Neurogen's obesity drug in phase 1 trial
13th Nov 2006, 19:47 GMT
Neurogen said Monday it initiated a phase 1 trial of its potential obesity treatment NGD-4715 in the United States.
Neurogen's obesity drug in phase 1 trial related news:
- Neurogen Announces Phase I Clinical Trial For Proprietary Obesity Drug — Health News from Medical News Today
- Neurogen commences human testing of obesity drug — Pharmaceutical Business Review Latest News
- Zydus Cadila files drug application to treat obesity — NewKerala Business India News
- Favrille drug fails secondary goal — Pharmaceutical Business Review Latest News
- Lilly drug reduces blindness in diabetic patients — Pharmaceutical Business Review Latest News
- Isis Pharma's shares soar on cholesterol-drug Phase II data — MarketWatch.com - Top Stories – Sponsored by: CyberTrader
- Vion Pharmaceuticals Reaches Midpoint Of Patient Accrual To Cloretazine(R) (VNP40101M) Phase III Trial — Health News from Medical News Today
- Reata brain cancer therapy shows strong activity — Pharmaceutical Business Review Latest News
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma — Bio-Technology News from StratCenter.com
- Volume 194, number 12: Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV-1 Vaccine among Injection Drug Users in Bangkok, Thailand — J Infect Dis Latest Issue
Latest news from United Press International - Health Business:
- AmerisourceBergen tests Rx tracking plan
- Lilly: Arxxant cuts sight loss in diabetes
- Merck: Arcoxia heart risk same as Voltaren
- Corcept tests psych. major depression Rx
- Analysis: Insurance horizons expanding
- Dendreon seeks OK for Provenge
- Robots caring for stroke patients
- Diabetes drug stalls heart disease
- Diabetes drug also helps arteries
- Promising vaccine for early breast cancer